Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb study assessing PAX-101 for Autism Spectrum Disorder

Trial Profile

A phase IIb study assessing PAX-101 for Autism Spectrum Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suramin sodium (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors PaxMedica
  • Most Recent Events

    • 05 Sep 2023 Status changed from recruiting to completed as per Paxmedica company pipeline.
    • 19 Aug 2021 According to a PaxMedica media release, company recently completed a pre-IND meeting with FDA to review the results of this trial as a first step toward conducting US clinical trials with PAX-101 in the near future.
    • 19 Aug 2021 According to a PaxMedica media release, David Hough will present trial results at the upcoming AACAP Annual Meeting during the Research Pipeline: New Findings on Diagnostics and Therapeutics program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top